Clarity Pharmaceuticals Ltd (ASX: CU6) Share Price and News

Dr Roberts joined the Board in March 2016 as a Non-Executive Director. He has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. He was previously the CEO of ASX-listed company Cochlear Limited and Chairman of ASX-listed company Sirtex Medical Ltd. He was also Executive Vice-President and a director of the dual-listed (ASX and NYSE) company ResMed Inc., a global sleep disorder treatment company. He is a non-executive director of ASX listed Sigma Healthcare Ltd, HMC Capital Ltd and HealthCo Health and Wellness REIT.

Ms Robinson brings over 25 years of board and executive leadership across the nuclear medicine, biotech, and health sectors, with deep expertise in commercial strategy, operational oversight, governance and stakeholder engagement across both public and private enterprises. She previously served as Chief Operating Officer of Cyclotek (Aust) Pty Ltd, where she led multi-site operations for radiopharmaceutical manufacturing across Australia and New Zealand. Prior to that, she was General Manager, Business Development at the Australian Nuclear Science and Technology Organisation (ANSTO), where she drove commercialisation and strategic partnerships across nuclear medicine and applied science portfolios for more than a decade. Her extensive experience in the nuclear field and radiopharmaceutical innovation positions her as a strategic contributor to the Groups board, offering clarity and foresight in a rapidly evolving segment of the healthcare industry. Her governance strength lies in distilling multifaceted business and operational issues into clear, strategic board insights.

Dr Taylor has been instrumental in shaping Claritys growth and strategy and has been closely involved across all areas of the Groups business. He has more than 15 years of investment banking experience, with a particular focus on the life sciences sector. He has significant expertise in capital raisings, mergers and acquisitions, and general corporate advisory and has been involved in approximately 2 billion of transactions prior to joining Clarity. Before joining Clarity, he was an Executive Director and shareholder of Inteq Limited, a boutique Australian investment bank.

Ms Rossiter is a healthcare executive with 25 years of global leadership across diagnostics, pharmaceuticals and medical technology. She has held senior leadership roles across all three Roche divisions, Pharmaceuticals, Diagnostics and Diabetes Care, and has lived and worked in the UK, Canada, the US and Australia. As Managing Director of Roche Diagnostics Australia, she led organisational transformation and Roche's national COVID-19 testing response. Ms Rossiter was later with an Australian Securities Exchange (ASX) listed diagnostics company and was most recently employed at Novartis as Country President for Australia and New Zealand. She began her career at Pfizer UK, before transitioning into healthcare leadership. She serves as Chair of the Board of SwissCham.

Ms Parker has over 20 years of experience spanning across nuclear medicine/PET and pharmaceutical industries both in Australia and internationally. Prior to joining the Group, He held the position of Head of International Clinical Research Operations at Novartis Australia, a global pharmaceutical company, leading a multi-disciplinary, high performing team of over 35 associates responsible for end-to-end clinical trial execution.

-

-

-

-